PIPELINE

OB001

OB001 is a preclinical peptide program derived from adiponectin biology. We engineer bioactive, post-translationally modified adiponectin-derived domains to target obesity and downstream metabolic dysfunction with a translation-first biomarker strategy.

Modality: PeptideStage: PreclinicalIndication: Obesity + metabolic disease
Teaser overview

Adiponectin biology is linked to metabolic homeostasis and inflammation. OB001 focuses on capturing activity that depends on structural features and complex post-translational modifications—then translating that biology into a manufacturable peptide therapeutic.

Mechanism anchor
Adiponectin pathway
Differentiation
PTM-enabled peptide domains
Translation
Biomarker-linked readouts
Path to clinic
IND-oriented package
Technology edge

OB001 is enabled by an in-house chemical biosynthesis platform that supports stereoselective glycan synthesis and ligation chemistry—unlocking complex peptide/protein architectures not easily accessible via standard recombinant workflows.

Complex glycopeptide synthesis
Structure-guided engineering
Scale-up readiness
Request OB001 summary (CDA)

We share full figures and protocols with qualified partners.

Preclinical focus (high-level)
Efficacy
Body composition + metabolic endpoints
Mechanism
Inflammation/metabolism biomarker modulation
Safety signals
Standard metabolic panels